Systemic lupus erythematosus (lupus or SLE) is an autoimmune disease that has impacted the lives of more than 1.5 million individuals in the United States. Lupus is one of several chronic conditions that may result in long-term disability. The majority of SLE sufferers are young women. It is imperative that healthcare providers, including nurses, have a general knowledge base regarding this chronic disease. In addition, this knowledge base will provide healthcare providers with the tools necessary to provide appropriate care, guidance, and support for patients who are living with this chronic disease process.
- INTRODUCTION
- EPIDEMIOLOGY
- TYPES OF LUPUS
- ETIOLOGY OF LUPUS
- SIGNS AND SYMPTOMS ASSOCIATED WITH LUPUS
- DIAGNOSIS OF LUPUS
- TREATMENT
- LUPUS AND REPRODUCTIVE HEALTH IN WOMEN
- LUPUS AS A CHRONIC ILLNESS
- RESOURCES FOR PATIENTS WITH LUPUS
- PATIENT EDUCATION
- CASE STUDY
- CONCLUSION
- Works Cited
- Evidence-Based Practice Recommendations Citations
This course is designed for nurses working in any healthcare setting who may interact with individuals diagnosed with systemic lupus erythematosus.
The purpose of this course is to provide nurses with the information necessary to provide appropriate care, guidance, and support for patients who are living with the chronic disease of systemic lupus erythematosus.
Upon completion of this course, you should be able to:
- Identify those individuals at risk for developing systemic lupus erythematosus (lupus).
- Compare and contrast the four types of lupus.
- Evaluate the possible causes of lupus.
- Identify common signs and symptoms of lupus.
- Select the laboratory tests and classification criteria necessary to appropriately diagnose lupus.
- Analyze the various treatment options for lupus.
- Discuss the impact of lupus as a chronic illness.
Richelle A. Rennegarbe, PhD, RN, earned her RN degree from Kaskaskia College in Centralia, IL, her BSN from McKendree University in Lebanon, IL, and her MS in Community Health Nursing from Southern Illinois University Edwardsville in Edwardsville, IL. She earned her PhD in Health Education from Southern Illinois University Carbondale in Carbondale, IL. Dr. Rennegarbe's primary areas of expertise include community health nursing, women's health issues, nursing leadership, and chronic conditions including systemic lupus erythematosus. She is a Professor of Nursing and Director of the DNP Program at McKendree University. Dr. Rennegarbe is certified by the American Organization for Nursing Leadership in executive nursing practice and certified as a Professional in Patient Safety by the Institute for healthcare Improvement.
Contributing faculty, Richelle A. Rennegarbe, PhD, RN, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Mary Franks, MSN, APRN, FNP-C
The division planner has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Sarah Campbell
The Director of Development and Academic Affairs has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.
Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.
It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.
Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported. Supported browsers must utilize the TLS encryption protocol v1.1 or v1.2 in order to connect to pages that require a secured HTTPS connection. TLS v1.0 is not supported.
The role of implicit biases on healthcare outcomes has become a concern, as there is some evidence that implicit biases contribute to health disparities, professionals' attitudes toward and interactions with patients, quality of care, diagnoses, and treatment decisions. This may produce differences in help-seeking, diagnoses, and ultimately treatments and interventions. Implicit biases may also unwittingly produce professional behaviors, attitudes, and interactions that reduce patients' trust and comfort with their provider, leading to earlier termination of visits and/or reduced adherence and follow-up. Disadvantaged groups are marginalized in the healthcare system and vulnerable on multiple levels; health professionals' implicit biases can further exacerbate these existing disadvantages.
Interventions or strategies designed to reduce implicit bias may be categorized as change-based or control-based. Change-based interventions focus on reducing or changing cognitive associations underlying implicit biases. These interventions might include challenging stereotypes. Conversely, control-based interventions involve reducing the effects of the implicit bias on the individual's behaviors. These strategies include increasing awareness of biased thoughts and responses. The two types of interventions are not mutually exclusive and may be used synergistically.
#34465: Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE), often referred to simply as lupus, is a chronic inflammatory autoimmune disorder of the connective tissue, primarily affecting the skin, joints, blood, and kidneys [1,2,3]. In this autoimmune disorder, antibodies are formed within the body that target healthy body systems, causing inflammation and structural changes. The word lupus means "wolf" in Latin, while erythematosus means "redness." The disease is named for the characteristic red rash that appears on the face and is thought to resemble a wolf's face [2,3]. The term "lupus erythematosus" was coined in 1851 by Pierre Cazenave, a French dermatologist, but writings describing lupus date to ancient Greece [3,4].
Lupus has been characterized as a multidimensional, unique, complex, challenging, unpredictable, and often elusive disease [2]. It is a non-organ-specific systemic disease with a varying prognosis that can be mild, serious, life-threatening, or even fatal. The disease is characterized by recurring remissions and exacerbations, often called flares, which may be triggered by ultraviolet exposure [1,5]. Periods of remission vary considerably among those diagnosed with lupus [2].
The number of reported cases of lupus varies based on different sources; it is believed that there are at least 16,000 patients diagnosed with all lupus types each year, and more than 1.5 million individuals affected at any given time in the United States. Worldwide, it is estimated that more than 5 million individuals have some form of lupus [6,8]. However, because lupus is relatively uncommon, difficult to diagnose, and not a reportable disease, epidemiologic studies are often expensive and tend not to produce reliable results on a large scale. A meta-analysis of the CDC National Lupus Registry network estimated that 204,295 people in the United States had SLE in 2018 (a prevalence of 72.8 per 100,000), with prevalence approximately 10 times higher in women than men and highest among Black women [63].
Mortality rates are also difficult to collect, but it is currently estimated that 10% to 15% of those diagnosed with lupus will die as a result of the disease [8]. Previously, this percentage was much higher, but improved diagnostic capabilities and treatments have drastically reduced mortality associated with lupus [4]. During the period 2018–2023, 6,414 death certificates listed SLE as the underlying cause of death [69].
Lupus is a significant cause of lost wages and disability in the United States. According to one survey, 55% of patients with lupus reported a complete or partial loss of income due to complications of the disease. One in three have been temporarily disabled by the disease, and one in four were receiving disability benefits [9]. On average, only 46% of people with lupus of working age report being employed [26].
A 2022 systematic review of U.S. studies found that mean annual direct healthcare costs ranged from $17,258 to $63,022 per patient, expressed in 2020 U.S. dollars, with higher costs generally associated with moderate to severe disease [70]. The average annual productivity cost (i.e., lost hours of economic productivity due to lupus) was between $1,200 and $20,000, making the total average annual cost for patients with lupus greater than $50,000 [7]. In addition, it was found that these estimates may be higher among people with lupus nephritis and more severe or active lupus [7].
More than 90% of SLE cases occur in women, with most women developing symptoms in their childbearing years (15 to 45 years of age) [11]. New diagnoses of SLE in women older than 45 years of age are uncommon [3]. SLE is most common among Black individuals, with Black women having three times the incidence of White American women. The incidence of lupus is also greater in Hispanic, Asian, and Native American women when compared to White women. Statistics show that Black and Hispanic women tend to develop the disease at a younger age, are more likely to develop more serious complications (particularly cardiovascular complications and kidney disease), and tend to have a higher mortality rate from the disease as compared to White women [11].
Four different forms of lupus have been identified: cutaneous lupus erythematosus (CLE), drug-induced lupus, neonatal lupus, and SLE [2]. CLE mainly affects the skin and can be acute or chronic, with skin eruptions that, if left untreated, can lead to scarring and permanent disfigurement. Drug-induced lupus is associated with ingestion of various drugs that result in lupus-like symptoms. Neonatal lupus is a rare, non-systemic condition affecting infants of women who have anti-Ro/SSA and/or anti-La/SSB antibodies (who may or may not have lupus). SLE, which affects multiple organ systems as well as the skin, is considered the most common of the four forms, accounting for 70% of all cases of lupus.
CLE is associated with various types of acute and chronic lupus, but the most prevalent form is discoid lupus erythematosus (DLE). DLE is often considered a mild form of lupus, while SLE is the most severe form of the disease [14]. An estimated 5% to 25% of individuals with DLE will develop SLE [10].
Symptoms of DLE include lesions that are patchy, crusty, raised, and/or red and scaling, typically nonpruritic plaques, with follicular plugging and central atrophy [2,5,10]. The lesions have a "coin-like" or discoid appearance and most commonly appear on the face or scalp but may appear on any part of the body. Facial lesions may form a "butterfly" pattern. The hair of an individual with DLE tends to be brittle or may fall out in patches. The lesions may resolve completely or result in hypopigmentation, hyperpigmentation, atrophy, permanent hair loss, or permanent scarring [2,4,10].
Diagnosis of DLE is based primarily on the patient's medical history and characteristic skin lesions. A skin biopsy may be performed to confirm the diagnosis and distinguish DLE from other skin conditions. Histopathologic examination typically reveals interface dermatitis, follicular plugging, and hyperkeratosis. Direct immunofluorescence may demonstrate deposits of immunoglobulins and complement components at the dermal-epidermal junction, which can support the diagnosis [2]. Patients with DLE should be evaluated for systemic disease with a clinical assessment and laboratory testing (e.g., ANA, CBC, urinalysis); a negative ANA makes SLE less likely but does not by itself rule it out. Management of DLE includes [2,12]:
Avoidance of prolonged sun exposure, fluorescent lighting, or reflected sunlight
Wearing protective clothing
Use of sunscreen with a minimum SPF of 50
Avoidance of sun exposure between 10 a.m. and 4 p.m.
Smoking cessation
Reporting changes in the lesions
Initiation of drug therapy that may include the topical, intralesional, or systemic medications used in SLE
Subacute CLE, or SCLE, is a subtype of cutaneous lupus that affects approximately 10% of patients with lupus [10,11]. Nearly half of patients with SCLE also have SLE. This condition is often induced by ultraviolet light exposure, and characteristic lesions present as a red ring-shaped patch with scaly borders and a light center, or scaly red bumps in sun-exposed areas [10,12]. Approximately 20% to 33% of SCLE cases are drug-induced [10]. Unlike DLE, subacute CLE lesions will not usually scar, but there is a potential for skin discoloration, which is often more severe on darker skin.
It is important to note that lupus lesions or rashes may appear different on individuals with brown or black skin. In contrast to the clinically defined "red" or "erythematous" color, lesions or rashes on patients with dark skin may present as dark purple or dark brown, making them easier to overlook. Healthcare professionals should be aware of the varying presentations of cutaneous lupus among individuals with darker skin tones [10].
Drug-induced lupus occurs as a consequence of the administration of various medications [14]. Approximately 15,000 to 30,000 new cases of drug-induced lupus erythematosus are estimated to occur annually in the United States [71]. Patients with drug-induced lupus tend to be older (between 50 and 70 years of age) than those diagnosed with SLE, mainly due to trends of medication use and polypharmacy in aging populations. No significant statistical difference is apparent in the prevalence for men versus women [15]. Ingestion of specific medications may result in symptoms similar to those seen in SLE, including fever, rash, arthritis pain, and inflammation of the lining around the heart and/or lungs, as well as lab findings consistent with SLE [2].
More than 100 medications have been implicated in drug-induced lupus, although the strength of evidence and the risk vary by drug [14,15]. Procainamide and hydralazine have the highest established risks of inducing systemic drug-induced lupus. Historical estimates suggest that approximately 15% to 20% of patients receiving long-term procainamide and 5% to 10% of those receiving hydralazine develop lupus-like symptoms [14,15]. Quinidine is also associated with drug-induced lupus, but its risk is substantially lower than that of procainamide or hydralazine. Other medications with well-established associations include isoniazid, minocycline, methyldopa, chlorpromazine, penicillamine, carbamazepine, ethosuximide, phenytoin, propylthiouracil, and sulfasalazine. Tumor necrosis factor (TNF) inhibitors, including etanercept, infliximab, and adalimumab, have also been associated with lupus-like syndromes, although fewer than 1% of treated patients develop clinical lupus. Other medications have been reported in association with drug-induced lupus or cutaneous lupus, but the evidence and risk are generally lower. Examples include certain beta-blockers, captopril, lithium, statins, and other medications. These associations should be interpreted in the context of the specific drug and the type of lupus manifestation [2,3,15]. The discontinuation of the medication precipitating drug-induced lupus usually results in resolution of the condition [2]. However, some patients require additional treatment to manage persistent or severe manifestations. Nonsteroidal anti-inflammatory drugs may be used for musculoskeletal symptoms, topical corticosteroids for skin involvement, and hydroxychloroquine or systemic corticosteroids for persistent or more significant disease. Severe organ involvement may require immunosuppressive therapy. Autoantibodies may remain detectable long after clinical symptoms resolve [15].
Infants born to women with lupus are at risk for a rare condition referred to as neonatal lupus, which is not a true form of lupus. It occurs when an infant passively acquires autoantibodies (anti-Ro/SSA and/or anti-La/SSB) from the mother, who may have SLE, Sjögren disease, another autoimmune condition, or no diagnosed disease [14]. Approximately 1% to 2% of infants born to anti-Ro/SSA–positive women will have this temporary condition; the number increases to 15% to 20% if a prior child was affected [2]. Women with lupus should be tested for anti-Ro/SSA and anti-La/SSB antibodies before or early in pregnancy; for those who test positive, the 2020 American College of Rheumatology (ACR) reproductive health guideline suggests serial fetal echocardiography from approximately 16 to 26 weeks' gestation and recommends hydroxychloroquine to reduce the risk of fetal heart block [64]. Infants with neonatal lupus may experience a rash, blood abnormalities, and liver problems. Most resolve by 6 months of age [14]. Some infants develop potentially serious complete heart block [5,6,14]. The heart block is treated with a pacemaker insertion [6]. In addition, approximately 25% of these infants are born prematurely [2].
As noted, SLE is a chronic inflammatory autoimmune disorder of the connective tissue and primarily affects the skin, joints, blood, and kidneys [1,2,3]. As the most common form of the disease, accounting for nearly 70% of all lupus cases, SLE will be the primary focus of this course [2]. Therefore, the term "lupus" will refer specifically to SLE for the purposes of this course.
The exact cause of lupus remains a mystery, but many researchers believe that it results from multiple factors [3,16]. Possible causes may be interrelated and include immunologic dysfunction, genetic factors, hormones, and environmental influences [4,5].
Immune dysregulation, in the form of autoimmunity, is thought to be the prime cause of lupus. In patients with lupus, the body produces an accelerated inflammatory response, resulting in the production of autoantibodies (antibodies to oneself), causing immune complexes (antigens combined with antibodies) [3,16]. These autoantibodies and complexes assault the body's own healthy cells and tissues [2,3,4,5]. Antigen-antibody complexes can attack or suppress the body's normal immunity and cause damage to tissues. Symptoms of lupus are the result of damage to the body's tissues secondary to the immunologic response.
SLE is a complex autoimmune disease involving abnormalities in both innate and adaptive immune responses. Dysfunction of T lymphocytes and B lymphocytes, impaired immune regulation, and the production of autoantibodies contribute to the development and progression of the disease. Autoantibodies can form immune complexes that promote inflammation and tissue damage in multiple organs, including the skin, joints, kidneys, blood vessels, and central nervous system. SLE may also affect blood cells, including red blood cells, white blood cells (such as neutrophils and lymphocytes), and platelets [2,3,5]. The presence of antinuclear antibodies (ANAs) is a hallmark of SLE, occurring in approximately 95% to 99% of affected individuals at some point during the disease course [2,3,5]. However, a positive ANA test alone does not establish a diagnosis because ANAs may also be present in healthy individuals and people with other conditions.
The strong hereditary component of lupus is supported by the fact that first- and second-degree relatives of patients with lupus are at a greater risk for developing lupus [17]. Estimates indicate that 5% to 13% of relatives will develop lupus, but only 5% of children whose mothers had lupus will develop the disease [17]. An immediate blood relative with a history of other autoimmune disorders, such as rheumatoid arthritis or scleroderma, also appears to place individuals at greater risk for developing lupus [4].
At this time, researchers have identified more than 100 loci linked to an increased susceptibility of lupus and have identified rare single-gene (monogenic) causes, such as deficiencies of early complement components (e.g., C1q, C4) and, more recently, a TLR7 gain-of-function variant [2,62]. Genetic factors contribute to susceptibility to SLE. The human leukocyte antigen (HLA) region, located within the major histocompatibility complex on the short arm of chromosome 6, is one of the strongest genetic susceptibility regions associated with SLE. HLA variants influence immune regulation and antigen presentation and have been associated with both SLE risk and the production of specific autoantibodies. However, SLE is a complex, multifactorial disease involving numerous genetic and environmental factors rather than a single causative gene or region [3]. A variant form of the STAT4 gene has also been associated with an increased risk for developing lupus. Researchers have found that persons with two copies of the disease-risk variant of the STAT4 gene have more than two times the risk for developing lupus compared to those with no variant form of the gene [18]. In a groundbreaking study published in 2022, researchers were able to pinpoint a single point mutation in the TLR7 gene of a child with severe lupus and to recreate the development of lupus with specific symptoms in laboratory mice [62]. Confirming that the mutation causes human lupus opens new opportunities to develop treatments [62].
The fact that women in their reproductive years are most susceptible to lupus indicates the possibility of hormone involvement in development of the disease. The female sex hormone estrogen can increase lupus activity [3]. As a result, disease flares may occur with pregnancy, in the days prior to menstruation, or in the postpartum period [2]. The ways in which, and to what degree, sex hormones affect the incidence and severity of lupus remain unclear and are topics of ongoing research.
For those with a genetic predisposition, environmental factors may trigger lupus [2]. Environmental factors that may precipitate or exacerbate lupus include physical or emotional stress, streptococcal or viral infections, exposure to sunlight, live vaccines (though not non-live vaccines), surgery, smoking, chemical agents (drugs, metals, or toxins), certain foods or supplements, and other environmental irritants (e.g., crystalline silica) [2,4,19]. As noted, the triggering or aggravating of lupus may also occur with pregnancy or an abnormal estrogen metabolism. Research is being conducted to determine the link between stress and the production of stress hormones (epinephrine and cortisol) and the triggering or exacerbation of lupus. Many patients with lupus report initial symptoms or flares with stressful events in their lives, such as divorce, birth, death of a loved one, or loss of a job [2].
No two people with lupus will experience identical symptoms. The onset of lupus may be acute or insidious, vague, or even nonspecific. On average, individuals with lupus have symptoms of the disease for two to three years before a diagnosis is made [3]. Symptoms are the result of the inflammatory and immune response of the individual's body to the disease process [3]. Repetitive cycles of exacerbations and remissions of symptoms are a hallmark of the lupus disease process.
Common symptoms of lupus include fever, weight loss, malaise, fatigue, skin rashes, polyarthralgia, vasculitis, Raynaud syndrome (discussed in detail later in this course), patchy alopecia (hair loss), and painless ulcers of the mucous membranes [5]. Fatigue is probably the most universal symptom, described as a persistent complaint of paralyzing fatigue that normal rest may not relieve [2]. Vague symptoms of lupus include aching, fatigue, low-grade or spiking fever, chills, and malaise. Episodic fever is reported by more than 80% of all patients with lupus, with a low-grade fever most often noted [2]. Infection is certainly a major concern and potential trigger for patients with lupus. Those with lupus are more susceptible to opportunistic infections due to immune dysfunction from the disease itself (including low white blood cell counts) and to immunosuppressive treatments. Women with lupus may also experience irregular periods or amenorrhea due to the disease process [2,3].
Skin rashes are very common among patients with lupus; approximately 80% of patients report skin involvement [2]. A red, raised rash over the nose and cheeks characterizes the classic malar or "butterfly rash" of lupus. The butterfly rash is reported by 55% to 85% of all patients with lupus at some point during their disease process [2]. Discoid lupus lesions may also be seen. Ultraviolet light often aggravates skin eruptions, and approximately half of all patients with lupus are found to be photosensitive [2,15]. Oral, nasal, and vaginal ulcers may occur. Conditions such as alopecia, pruritus, alteration in wound healing, and bruising are other common dermatologic symptoms. An additional cutaneous symptom is termed livedo reticularis. This condition occurs due to a disordered blood flow near the surface of the skin [3]. It is a reddish mottling or cyanotic lace-like pattern seen on the arms, legs, or torso of the body, especially apparent in cold weather [2].
Polyarthralgia (pain in multiple joints) occurs in more than 90% of lupus cases [2]. The joint pain associated with lupus is similar to that experienced by rheumatoid arthritis patients and is often called lupus arthritis. Most patients complain of morning joint stiffness and pain. The pain is typically symmetrical, and joints may become tender, warm to the touch, and swollen. The dominant extremities are usually more inflamed. Joints commonly affected include the toes, ankles, fingers, wrists, elbows, and knees [20]. Joint pain is often one of the first and most common complaints of those with lupus and is often what initially brings them to a healthcare provider [4]. Additional musculoskeletal symptoms that may occur include subcutaneous nodules, tendonitis, tendon rupture, and carpal tunnel syndrome [2].
Anemia occurs in approximately 50% of all individuals with lupus [21]. The anemia can result from various factors, including low iron levels, medications, gastrointestinal bleeding, or autoantibody formation to red blood cells [2]. Leukopenia, a decrease in white blood cells, is common in patients with lupus but is rarely significant enough to cause infection [21]. In addition, thrombocytopenia, a low platelet count, may occur [5]. This condition can occasionally result in bleeding problems; blood clotting problems are more often related to antiphospholipid antibodies for patients with lupus [4]. Lymph node enlargement is also a potential symptom of lupus.
Two key symptoms in lupus, especially prior to diagnosis, are weight loss and anorexia. These two symptoms are also common to numerous other health conditions and may not be linked to the diagnosis of lupus. Abdominal pain, dysphagia, gastroesophageal reflux, nausea, vomiting, diarrhea, and constipation are also potential symptoms [22]. Hepatic involvement may result in liver enlargement, jaundice, hepatic vasculitis, Budd-Chiari syndrome (obstruction of the hepatic veins, usually by a blood clot), ascites (fluid accumulation in the abdomen), and abnormal liver function tests [22]. Pancreatitis is another potential complication, occurring in about 5% of patients with lupus [2,3].
Approximately 50% of patients with lupus develop symptoms of cardiopulmonary abnormalities, including pericarditis, myocarditis, endocarditis, and tachycardia. People with SLE have an increased risk of premature atherosclerosis and cardiovascular disease. Chronic inflammation, traditional cardiovascular risk factors, and some treatment-related effects contribute to the development of atherosclerotic plaques, increasing the risk of coronary artery disease, myocardial infarction, and stroke. Pleurisy, parenchymal infiltrates, dyspnea, pneumonitis, and edema in the extremities are also common. The most common cardiac complication of lupus is pericarditis, while pleurisy is the most common respiratory complication [2,3]. SLE may cause increased pressure in the pulmonary circulation, including pulmonary arterial hypertension. Contributing mechanisms include inflammation and dysfunction of pulmonary blood vessels; pulmonary hypertension may also result from interstitial lung disease, left-sided heart disease, or chronic thromboembolic disease. Symptoms include progressive shortness of breath, fatigue, reduced exercise tolerance, and chest pain.
Shrinking lung syndrome, a rare complication, reported in approximately 1% to 2% of patients with SLE, is characterized by reduced lung volumes and impaired respiratory function without significant underlying lung tissue disease. The exact mechanism is unclear but may involve diaphragmatic dysfunction, reduced chest wall expansion, or pleural inflammation.
Vascular symptoms may include vasculitis or Raynaud syndrome. Vasculitis may include necrotic ulcerations that occur most frequently on the lower legs, ankles, and dorsa of the feet [2]. Raynaud syndrome can develop, especially in the digits of the hands and feet, secondary to stress, cold, or vibratory stimuli [3]. This condition is caused by sudden onset of vasospasms of the fingers and toes. The vasospasms cause the digits to tingle and the extremities to turn red, blue, or white in color. In serious cases, it can lead to infarctive lesions, necrotic ulcers, or gangrene. This form of cold sensitivity occurs in approximately 40% of patients with lupus [23].
An additional cutaneous symptom is termed livedo reticularis. This condition occurs due to a disordered blood flow near the surface of the skin [3]. It is a reddish mottling or cyanotic lace-like pattern seen on the arms, legs, or torso of the body, especially apparent in cold weather [2].
Renal damage is one of the most serious complications of lupus, often causing such symptoms as hematuria, proteinuria, urine sediment, cellular casts, urinary tract infections, and fluid/electrolyte imbalance. Renal involvement (lupus nephritis) affects up to 50% of patients with lupus, and approximately 10% to 20% of patients with lupus nephritis progress to kidney failure within 10 years [2,66]. Renal involvement, particularly lupus nephritis, is a major cause of morbidity in patients with SLE [72].
Nervous system involvement secondary to lupus is common and can range from mild to severe. Central nervous system involvement may result in cognitive disorders, including confusion, fatigue, memory impairment, and difficulty in articulating thoughts [3]. Cognitive dysfunction is estimated to occur in up to 90% of patients with lupus and is not associated with lupus disease activity [27]. Other neurologic conditions may include convulsive disorders or seizures, mental dysfunction, stroke, paralysis, behavioral changes or emotional instability, headaches, psychosis, acute confusional state, dizziness, irritability, and depression [4,5]. In addition, those diagnosed with lupus are twice as likely to experience migraine-like headaches [3]. Central nervous system conditions rank only behind renal disease and infection as a leading cause of death for those diagnosed with lupus [2].
Ophthalmic disease affects approximately 20% of patients with lupus [2]. Ophthalmic symptoms associated with lupus may include a lupus rash on the eyelids, conjunctivitis, dry eyes, glaucoma and cataracts (often related to corticosteroid therapy), and retinal vasculopathy [2]. In severe cases, retinal exudates or blindness may occur.
The diagnosis of lupus may be a challenge for the healthcare provider as well as the patient. A diagnosis of lupus is typically made when an individual has characteristic clinical features, often involving more than one organ system, together with supportive laboratory findings such as autoantibodies [24]. It is not uncommon for patients with lupus to have consulted with three to five physicians before a definitive diagnosis of lupus is given [3]. As stated previously, an average delay of two to three years from the onset of symptoms to the time of diagnosis is common [3]. In addition, patients with lupus may have a variety of healthcare professionals caring for them due to multiple organ system involvement and a wide range of symptoms. This may result in confusion and information gaps for the patient and healthcare providers [2].
The diagnosis of lupus can be facilitated with a physical examination, extensive patient history, various laboratory tests, and radiographic evaluations [3,5]. There are several laboratory procedures that help to diagnose and monitor individuals with lupus; these various tests have different implications for the patient (Table 1) [2,3,5,24,25].
LABORATORY TESTS AND THEIR IMPLICATIONS IN LUPUS
| Laboratory Tests | Implications |
|---|---|
| Complete blood count (CBC) (includes red blood cells, white blood cells, platelets, hemoglobin, and hematocrit) | Anemia, risk for infection, bleeding disorder |
| Liver screening panels | Hepatitis, jaundice, hepatic abnormalities |
| Serum creatinine | Elevated levels present in renal impairment |
| Antinuclear antibody (ANA) test | Identifies presence of autoantibodies; 97% of patients with lupus have a positive ANA |
| Syphilis serology test or rapid plasma reagin (RPR) | Syphilis test that may be falsely positive in patients with lupus |
| Urinalysis | Can indicate the presence or extent of renal disease |
| Spot urine protein-to-creatinine ratio (UPCR) and estimated GFR | Measures renal function impairment |
| Erythrocyte sedimentation rate (ESR) | Measures generalized inflammation |
| C-reactive protein (CRP) | Measures generalized inflammation |
| Anti-dsDNA antibody test | Immunoglobulin specific against DNA; highly specific test for lupus and associated with serious organ-threatening disease; 40% to 80% of patients with lupus have a positive anti-dsDNA |
| Anti-Sm antibody test | Immunoglobulin test; highly specific for lupus; 20% to 30% of patients with lupus have a positive anti-Sm |
| Complement components (C3, C4, CH50) | Proteins that mediate inflammation. Evaluates kidney involvement and disease over time; low complement levels occur during lupus flares |
| La antibody test or anti-SSB | Immunoglobulin; coexists with anti-SSA; associated with neonatal lupus; present in 15% of patients with lupus |
| Ro antibody test or anti-SSA | Immunoglobulin; found with anti-SSB; associated with neonatal lupus and photosensitivity; present in 20% to 30% of patients with lupus |
| Antiphospholipid antibody (APL) | Autoantibodies that react with phospholipid; includes anticardiolipin; present in 30% to 40% of patients with lupus |
| Rheumatoid factor (RF) | Commonly positive in rheumatoid arthritis but may be positive in patients with lupus |
The antinuclear antibody (ANA) test is the most sensitive (but not specific) screening test for lupus and is therefore the most commonly used autoantibody test. Ninety-seven percent of patients with lupus have a positive ANA blood test. The titer and patterns of the blood sample are reported. A titer of 1:80 or higher is usually considered positive [24]. It is important to note that a positive ANA test is found in 97% of patients with lupus, but alone, it does not indicate a conclusive diagnosis of lupus [24]. A positive ANA test (titer of 1:80 or higher) is the required entry criterion for the 2019 EULAR/ACR classification criteria discussed below [28]. ANA tests may also be positive in patients with other connective tissue diseases, chronic infectious diseases, and autoimmune diseases, which is why testing should only be ordered when clinical suspicion exists [67].
Other laboratory tests are available to assist in diagnosis or to monitor the effects of treatment. The anti-double-stranded-DNA (anti-dsDNA) blood test indicates disease activity, especially renal involvement. The anti-dsDNA test is most often used to monitor response to treatment. In remission, the anti-dsDNA test response is reduced or absent. In addition, the complement assay levels can assist with the diagnosis and monitoring of active lupus. The most commonly measured complement components associated with lupus are C3, C4, and CH50. When these complement levels are decreased, they can indicate an increase in disease activity [22].
Skin and kidney biopsies can also be used in the diagnosis of lupus. Biopsies assist in determining disease presence in organs as well as tissues. Kidney biopsy determines the disease stage and extent of renal involvement secondary to lupus. A chest x-ray can identify pleurisy or lupus pneumonitis, while an electrocardiogram can be used to indicate conduction defects that may occur with cardiac involvement or pericarditis.
As noted, lupus is a condition that is often difficult to diagnose due to the significant variation of symptoms among individuals. In 2019, the European Alliance of Associations for Rheumatology (formerly the European League Against Rheumatism) (EULAR) and the American College of Rheumatology (ACR) published updated classification criteria for lupus (Table 2) [28]. The EULAR/ACR criteria classify a person as having lupus if they meet the entry criterion of an ANA titer of ≥1:80, followed by additive weighted criteria (seven clinical and three immunologic domains) in which the patient must meet one clinical criterion and ≥10 points between the clinical criteria and immunologic criteria [28]. Within each domain, only the highest-weighted criterion is counted; criteria need not occur simultaneously; and a criterion should not be counted if there is a more likely explanation than SLE. Classification criteria were developed to identify patients for research and are not intended to be used as diagnostic criteria for individual patients [28].
2019 EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS
| Domain | Criteria | Weight | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Entry Criterion | ||||||||||
| Positive antinuclear antibody (ANA) titer | ANA titer of ≥1:80 on HEp-2 cells or an equivalent positive test (ever) | Must be positive to continue to additive criteria | ||||||||
| Additive Criteria, Clinical | ||||||||||
| Constitutional | Fever | 2 | ||||||||
| Hematologic |
|
| ||||||||
| Neuropsychiatric |
|
| ||||||||
| Mucocutaneous |
|
| ||||||||
| Serosal |
|
| ||||||||
| Musculoskeletal | Joint involvement | 6 | ||||||||
| Renal |
|
| ||||||||
| Additive Criteria, Immunology | ||||||||||
| Antiphospholipid antibodies |
| 2 | ||||||||
| Complement proteins |
|
| ||||||||
| SLE-specific antibodies |
| 6 | ||||||||
Although it is very difficult to determine the exact number of individuals diagnosed with lupus each year, diagnoses of lupus appear to be increasing. This may be linked to several factors, including improved diagnostic tests, a larger number of individuals seeking health care, increased public awareness, and specific diagnostic criteria. Literature on lupus makes it clear that in order to effectively combat this illness, quick and efficient diagnosis and aggressive treatment are essential [4].
There is currently no cure for lupus, and long-term disease management is required. Due to the variability of lupus symptoms, treatment protocols differ for each individual. The range of treatments, however, is increasing in number and becoming more effective; thus, the disease can be controlled reasonably well in most people. According to the U.S. Department of Health and Human Services (USDHHS), "the best way to treat lupus is to listen to the patient, whether she or he was diagnosed today or years ago" [2]. The goals of treatment for systemic lupus erythematosus (SLE) are to achieve and maintain disease remission or low disease activity, control inflammation, prevent disease flares and irreversible organ damage, reduce morbidity and mortality, and minimize treatment-related adverse effects. Treatment is individualized according to disease activity, the organs involved, and the patient's clinical characteristics and preferences [61].
Treatment is based on such factors as symptoms and severity, overall general health, activity level, school and/or family schedule, age, family and social situations, other medical conditions, and financial and insurance considerations [4].
Individuals diagnosed with lupus are encouraged to prioritize the following [2,3,4,5]:
Get plenty of physical and emotional rest.
Maintain a healthy diet.
Establish an exercise regimen.
Avoid sunlight.
Seek prompt treatment of infection.
Limit stress.
Set realistic goals and priorities.
Maintain effective communication with their healthcare providers.
Develop a support system, including family, friends, healthcare professionals, community organizations, and organized support groups.
Avoid triggering or aggravating factors, including smoking.
Seek regular health care, including recommended (non-live) vaccinations and screening for cardiovascular risk factors and bone health.
Eight to 10 hours of sleep per night along with naps are recommended for patients with lupus. In addition, individuals with lupus should minimize stress to reduce emotional distress, as well as avoid direct prolonged sunlight, especially during the hours between 10 a.m. and 4 p.m. The use of a sunscreen with a sun protection factor (SPF) of 50 or greater that protects against both ultraviolet A and B rays is recommended along with protective clothing such as long sleeves and a hat [2]. Routine exercise is important to reduce fatigue and maintain joint mobility.
Although there is no cure for lupus, there are several types of drugs available to aid in the treatment and management of secondary symptoms. Among these drug classes are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antimalarials, immunosuppressives, and biologics (including monoclonal antibodies). In cases of severe lupus kidney disease not helped by pharmacologic intervention, dialysis or kidney transplant may be necessary.
Hydroxychloroquine sulfate is recommended for all patients with lupus unless contraindicated, at a dose not exceeding 5 mg/kg of actual body weight per day [61]. Although developed as an antimalarial, it modulates the immune response, reduces flares and organ damage, and improves survival. In addition, it may act as an anticoagulant and cholesterol reducer [5]. Possible side effects of antimalarials include rash, nausea, and headache. A serious potential side effect of antimalarial drugs is retinal damage. A baseline eye examination is recommended within the first year of treatment, with annual screening beginning after five years of use (or sooner for patients with risk factors such as doses above 5 mg/kg/day or kidney disease) [65]. Rare but serious adverse effects also include QT prolongation, cardiomyopathy, and hypoglycemia.
NSAIDs, such as ibuprofen, naproxen, and indomethacin, may be used for short-term relief of joint pain, inflammation, and fever. NSAIDs reduce inflammation by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis. Potential adverse effects include gastrointestinal irritation, ulcers and bleeding, kidney injury, fluid retention, and increased blood pressure. Their use requires particular caution in patients with lupus nephritis or impaired renal function.
Selective cyclooxygenase-2 (COX-2) inhibitors are alternative options for selected patients. Celecoxib is currently the only COX-2 inhibitor available in the United States; rofecoxib and valdecoxib were withdrawn from the market in 2004 and 2005, respectively, due to cardiovascular risks (and, for valdecoxib, serious skin reactions). All prescription NSAIDs, including COX-2 inhibitors, carry an FDA boxed warning for an increased risk of serious cardiovascular thrombotic events and gastrointestinal bleeding.
In 2011, the U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of lupus—the first in more than 50 years [31]. The medication, belimumab, is a human monoclonal antibody that inhibits B-lymphocyte stimulator and acts to suppress abnormal B cells. Clinical trials have demonstrated that belimumab, when added to standard therapy, can reduce disease activity in patients with active SLE. However, results from the EMBRACE trial, which specifically evaluated adults who self-identified as Black, were not statistically significant for the primary endpoint, although outcomes numerically favored belimumab [73]. Subgroup analyses suggested greater benefit among patients with high disease activity or renal involvement. These findings underscore the importance of further research to better understand treatment response across diverse patient populations. The drug has been approved to treat patients with active, autoantibody-positive lupus who are receiving standard therapy [13,31]. It is administered via intravenous infusion or as a weekly subcutaneous injection (approved for adults in 2017 and later extended to pediatric patients), and infusion and hypersensitivity reactions may occur. Premedication (e.g., with an antihistamine and antipyretic) may be considered, although it has not been shown to prevent these reactions. Other possible side effects of belimumab use include fever, diarrhea, and nausea [31]. Two observational studies—one conducted in the United States and one conducted in Canada—found that patients with lupus who received eight or more infusions of belimumab plus standard of care for up to 24 months demonstrated improvements in disease severity and laboratory values. The patients also showed a reduced use of oral steroids and a reduced use of healthcare resources as early as six months from the start of belimumab therapy [32,33]. In 2019, belimumab was approved by the FDA for pediatric patients 5 years of age or older [54]. Additionally, in 2020, belimumab received approval for adults with active lupus nephritis receiving standard therapy, with approval extended to pediatric patients with lupus nephritis in 2022 [57].
In 2021, the FDA issued approval for anifrolumab, a human monoclonal antibody directed against type I interferon receptor subunit 1 (IFNAR1), for treatment of adults with moderate-to-severe systemic lupus who are receiving standard therapy [13,57,58]. Anifrolumab blocks the biologic activity of type I interferon receptors that, when elevated, play a role in the pathogenesis of systemic lupus. The agent has been shown to reduce inflammatory and immunological processes in systemic lupus [13,58]. Anifrolumab is administered by IV infusion or subcutaneous injection, and the most common adverse reactions include nasopharyngitis, upper respiratory tract infection, bronchitis, infusion-related reactions, and herpes zoster [13]. Anifrolumab is not approved for the treatment of lupus nephritis or lupus affecting the central nervous system. Anifrolumab is often used in combination with other drugs, such as hydroxychloroquine and glucocorticoids [13,57].
Another monoclonal antibody, rituximab, has shown promise in the management of lupus, though not FDA-approved for the treatment of SLE [13,59,60]. Many open-label studies have shown improvements in lupus symptoms with the use of rituximab, including in patients with severe and/or refractory disease, but two large randomized, double-blind studies failed to show major clinical response compared with placebo [59,60]. The 2023 EULAR recommendations support considering off-label rituximab in patients with refractory organ-threatening disease [61]. In 2025, the FDA approved obinutuzumab, a type II anti-CD20 monoclonal antibody, for adults with active lupus nephritis who are receiving standard therapy, based on the phase 3 REGENCY trial [68]. Other agents under investigation include deucravacitinib, litifilimab, dapirolizumab pegol, and CD19-directed chimeric antigen receptor (CAR) T-cell therapy.
In moderate-to-severe lupus, corticosteroids may be prescribed. Corticosteroids are also known as, or include, glucocorticoids, steroids, cortisone, and prednisone. Prednisone is used for treating lupus conditions impacting major organs. The drug is responsible for rapidly suppressing the immune system, which results in a reduction of inflammation, pain, and fatigue secondary to the autoimmune response [2,5]. Prednisone doses are tapered off as soon as symptoms are under control. Prednisone is a very powerful drug with numerous potential side effects, including osteoporosis, osteonecrosis, hypertension, hyperglycemia, coronary artery disease, visual changes, excessive hunger with weight gain, bruising, insomnia, acne, hair loss, and alterations in the immune system, such as increased risk of infection or delayed healing. At doses of more than 40 mg/day, it has also been associated with several neuropsychiatric disorders [34]. Therefore, the dosage is reduced as quickly and safely as possible. Prednisone should not be discontinued suddenly, especially if it is taken for four weeks or longer [2]. Instead, prednisone doses should be tapered off slowly to prevent potential complications. The 2023 EULAR recommendations advise minimizing chronic glucocorticoid use to a maintenance dose of 5 mg/day or less of prednisone equivalent and withdrawing glucocorticoids when possible; intravenous methylprednisolone pulses may be used for severe, organ-threatening disease [61].
Cytotoxic or immunosuppressive drugs, such as voclosporin, methotrexate, azathioprine, cyclosporine, cyclophosphamide, and mycophenolate, are the most effective drugs used for serious, life-threatening lupus or for patients taking high doses of prednisone [2]. Cytotoxic drugs are administered intravenously or orally. They are primarily used in patients with lupus-related kidney, lung, or brain complications. Mycophenolate mofetil, an immunosuppressive drug, is now a recommended first-line therapy for induction and maintenance in lupus nephritis, often in combination with belimumab or a calcineurin inhibitor (voclosporin or tacrolimus) [61,66]. Mycophenolate is teratogenic and must be discontinued at least 6 weeks before conception [64]. Several of these drugs (e.g., mycophenolate, azathioprine, cyclosporine) are also used to prevent rejection of transplanted organs, and all pose considerable risks [4]. Potential side effects of cytotoxic drugs include fatigue, oral ulcers, gastrointestinal complications, liver complications, ovarian or testicular failure, alopecia, and immunosuppression, including bone marrow suppression [2]. In addition, the use of these drugs may increase the risk of developing future malignancies in patients with lupus [2].
Voclosporin is a novel calcineurin-inhibitor immunosuppressant that received FDA approval in 2021 for use in adult patients with lupus nephritis. Voclosporin is given orally, in combination with other drugs, including hydroxychloroquine, corticosteroids, and/or mycophenolate [13,57]. Safety and efficacy have not been established when used in combination with cyclophosphamide; the use of these drugs concomitantly is not recommended [13]. Side effects include hypertension (potentially severe), decreased glomerular filtration rate, diarrhea, infection, anemia, and headache; voclosporin carries a boxed warning for malignancies and serious infections [13].
Lupus usually strikes women in their childbearing years (15 to 45 years of age), and the disease process can impact pregnancy. Women with lupus have a higher incidence of pre-eclampsia, spontaneous abortion, premature delivery, and pregnancy-induced hypertension than those without the disease. In addition, pregnant patients with lupus may have an increased risk for a lupus flare during pregnancy and during the immediate postpartum period, but the association between pregnancy and lupus flares remains controversial—at this time, it is unclear whether flares are caused by pregnancy or are related to spontaneous fluctuations in disease activity [37]. Experts recommend low-dose aspirin beginning by 12 to 16 weeks' gestation for pregnant patients with SLE to reduce the risk of pre-eclampsia [64].
Prior to the mid-1980s, women with lupus were advised not to become pregnant due to a potential for disease flare or miscarriage; the miscarriage rate in the 1960s for women with SLE was 43% [2,37]. Since then, experts have estimated that 17% of lupus pregnancies end in miscarriage, which is comparable to non-lupus pregnancies (15% to 20%) [29,37,38]. However, specific populations still have a higher risk of lupus-related miscarriage. Outcomes vary according to disease activity, lupus nephritis, antiphospholipid antibodies, hypertension, and other clinical and socioeconomic factors. In the prospective PROMISSE study, 19% of patients with SLE who had inactive or stable disease at enrollment experienced a defined adverse pregnancy outcome, although the findings may not apply to patients with more active disease or severe organ involvement [39,40]. Racial and ethnic disparities in pregnancy outcomes have been reported, but they should not be attributed solely to race or presumed differences in disease activity; clinical factors and social determinants of health may also contribute.
Nonetheless, research and improved treatment have made a substantial difference in the outcomes for pregnancy. Available evidence indicates that a woman with lupus can have a safe, successful pregnancy, particularly if disease activity can be minimized. Those considering pregnancy should ideally have quiescent disease for at least six months before conception while taking pregnancy-compatible medications; hydroxychloroquine should be continued during pregnancy, whereas teratogenic drugs (e.g., mycophenolate, methotrexate, cyclophosphamide) must be stopped in advance [37,64]. Flare rates in pregnancy are also significantly reduced when patients are in remission for six months prior to conception (7% to 33% versus 61% to 67% in women with active disease at conception) [37]. One small study published in 2020 found that the risk of major flare during pregnancy was low (4.1%) when conception happens during stable disease [29]. Women with lupus should be monitored closely by their physician and an obstetrician throughout the course of the pregnancy. It is recommended that female patients with lupus use reliable birth control to prevent harm to the fetus from drugs used to treat lupus and in order to ensure that conception occurs only during periods of sustained remission [41].
According to the USDHHS, one-third to one-half of women with lupus have an anticardiolipin antibody and lupus anticoagulant [2]. These two autoantibodies have been associated with an increased incidence of miscarriage. Women considering pregnancy or who become pregnant should have blood tests to screen for these two antibodies [37]. Women who have a history of miscarriage and have tested positive for these two autoantibodies can be treated with low-dose aspirin and prophylactic-dose heparin (typically low-molecular-weight heparin) during the pregnancy [64].
There has been controversy as to whether women with lupus should take oral contraceptives and/or receive hormone replacement therapy (HRT) during menopause. Estrogen is believed to increase the risk of lupus flares; however, research regarding the role of sex hormones in disease flares has been mixed. A study conducted in 2005 indicated that estrogen contained in oral contraceptives and HRT did not increase the risk of flare in women whose disease is stable [2,42]. Estrogen-containing contraceptives should be avoided in patients with positive antiphospholipid antibodies because of the risk of thrombosis [64]. However, an observational study found that the use of combined oral contraceptives, particularly recent initiation of use, increased the risk of developing SLE [43]. There were some concerns regarding the applicability of this study information in women of color. Although there is an increased confidence in the benefits of estrogen outweighing the risks, more research is needed in this area and the patient and physician must always weigh the options and closely monitor signs of potential problems. Intrauterine devices (levonorgestrel or copper) are highly effective and are recommended as a preferred contraceptive option for many women with lupus, including those with positive antiphospholipid antibodies [64].
Numerous illnesses are considered chronic in nature. Various chronic illnesses include diabetes, asthma, congestive heart failure, and rheumatoid arthritis. Lupus is considered to be a chronic illness due to its cyclical nature of exacerbation and remission of symptoms. Chronic illnesses such as lupus can be challenging to the patient due to the physical, psychological, social, and financial impact of the disease.
When most individuals think about chronic illness, they tend to picture illnesses found predominantly in elderly individuals. Chronic illnesses such as lupus, however, are not limited to a specific age group. In fact, lupus usually strikes individuals in the prime of their life.
Chronic illness and disability not only result in the loss of physical aspects of the individual's life but may also impact the psychological, familial, social, and vocational aspects of the affected individual's life [1]. The impact chronic disease will have on an individual is dependent on various factors, including the nature of the condition, the individual's pre-illness or pre-disability personality, current life circumstances, and the amount of family and social support in the individual's environment [1]. All of these disease factors can impact the patient's perception and experience of lupus. Due to the young age at disease onset, most individuals with lupus can expect to face many years managing their chronic condition.
In addition to physical symptoms, those with lupus may experience psychological and emotional manifestations that may result from the physical symptoms of and treatments for the disease. Because many individuals who receive the diagnosis of lupus are relieved to finally have a name for the condition that afflicts them, the chronic nature of the condition may not be of immediate importance [44]. Initially, the individual may be more focused on treating the symptoms of lupus rather than the realization that there is no cure. Individuals with lupus face the uncertainty of the disease process, including the unpredictability of disease flares and remissions. Thus, living with a chronic disease like lupus can be overwhelming for patients, marked by uncertainty and the potential loss of function secondary to the disease process [1].
Generally, those with lupus are in the young adult development stage of life when an initial diagnosis is made. Lupus may cause alterations in the individual's ability to achieve specific tasks fundamental to this developmental stage. Common tasks or activities for the young adult's developmental goal achievement generally include gaining independence, achievement of vocational goals, establishment of intimate relationships, social responsibility, childbearing, and childrearing [1]. Limitations in any of these developmental activities for this specific age group can result in challenges for the individual diagnosed with lupus.
The psychological impact of lupus can be variable. Lupus may impact family life, work, sexual activity, social activities, finances, and day-to-day living [4]. The diagnosis of lupus may impact one's current lifestyle and result in a need for changes in that lifestyle pattern. It may affect the ability to maintain employment status, alter financial stability, and create a potential for the loss of a role, status, or independence. Being diagnosed with a chronic illness may result in a wide range of reactions, including anxiety, fear, shock, denial, negative self-esteem and body image, and self-blame [4]. Feelings of isolation, grief, stress, guilt, anger, loss of control, decreased confidence, depression, hopelessness or helplessness, irritability, and suicidal ideations are also common in those with a chronic illness such as lupus [1,2,3].
Both the perception and importance that an individual and his or her family attribute to a chronic illness can affect the individual's ability to accept the condition and make the adjustments necessary to cope [1]. Illness and disability can impact the relationships of the person diagnosed with the chronic illness. Individuals may fear the loss of a relationship secondary to their chronic illness condition; therefore, they may try to conceal the impact of the condition on their life in order to maintain the relationship [45].
Baker and Wiginton found that study participants "expressed concern that others in their lives did not understand lupus and failed to acknowledge the seriousness of their conditions due to the symptoms not being readily apparent" [44]. Family and friends may deny that the disease is a problem, fail to assist the individual, or fail to understand the disease, particularly if the individual shows no outward signs of the disease. Falvo terms this "invisible disability" [1]. Lupus is one such invisible chronic illness. Additionally, some people may be uncomfortable being in a relationship with an individual with a chronic illness like lupus. They may not know what to say, worry about saying the wrong thing, or fear that the chronic disease is contagious.
Sexuality and interpersonal issues may also be impacted by a chronic illness. Physical limitations, lack of energy, pain, alterations in self-image, or other reactions may impact the sexuality of an individual with lupus [1]. Sexual dysfunction is a recognized concern among women with systemic lupus erythematosus (SLE) and may include reduced sexual desire, impaired arousal or lubrication, difficulty achieving orgasm, pain during intercourse, and reduced sexual satisfaction. A 2026 systematic review and meta-analysis estimated that approximately 59% of women with SLE experience sexual dysfunction, although prevalence estimates vary widely across studies [35]. Potential contributing factors include fatigue, pain, depression, disease-related physical changes, hormonal factors, and medication effects. Sexual difficulties are not universal, and clinicians should assess patients' concerns individually. Open communication and knowledge regarding the lupus disease process can prevent uncertainty and issues regarding sexuality.
Some individuals with a chronic condition like lupus do not want to burden or inconvenience those around them; thus, they attempt to manage the disease on their own. Individuals with a chronic illness should make families aware of the necessity for adjustments or alterations in roles and tasks secondary to the lupus disease process. Families should be aware of the fact that lupus requires ongoing care and treatment to effectively control the disease. Some men with SLE report barriers to seeking support or identifying with a condition commonly perceived as affecting women. However, responses to chronic illness vary considerably among individuals, and assumptions based on gender should be avoided [45].
Ongoing management of a chronic disease such as lupus is imperative [46]. Baker and Wiginton found in their research that the majority of the participants engaged in self-management for controlling their lupus [44]. Individuals with lupus who understand the impact of having a chronic illness, as well as the skills necessary to control this type of condition, can increase the likelihood of successful disease management.
According to Phillips, one of the most central aspects of coping with lupus has to do with gaining control of one's life [4]. The use of effective coping strategies can enable an individual to manage his or her emotions. In research completed on coping, psychological adjustment, and health status among women with lupus, it was found that women who engaged in avoidant coping (failing to engage in coping strategies) were more likely to suffer from depression and had greater fatigue and a lower health status [47]. The researcher also indicated that there is a paucity of research on the psychosocial aspects of lupus, especially regarding coping with lupus and its impact on psychological adjustments and health status [47].
Coping strategies are used "to manage, tolerate, or reduce the stress associated with significant life events and to attempt to restore psychological equilibrium after a stressful or traumatic event" [1]. Coping strategies can be adaptive (effective) or maladaptive (noneffective). Individuals have the propensity to engage in coping strategies that have been previously effective. If coping strategies become ineffective, then they can alter strategies in an attempt to cope and manage the chronic illness [1]. It is critical to the individual with lupus that he or she engage in effective coping strategies to reduce stress, maintain psychological well-being, and regain control of the situation. Phillips indicated that successful living with lupus can be achieved by taking charge, seeking information, developing a positive relationship with one's physician, and assisting one's family with adjusting to the diagnosis [4].
Tremendous stress may be associated with managing a chronic illness. The loss of control related to the chronic disease can exacerbate the stress level for an individual. Stress also may be elevated by the compromising of roles and changes in the level of functioning [1]. It is vitally important that an individual's personal perception of the stresses associated with the disease, as well as their capacity to cope, be considered, as perceptions of stress and coping abilities will vary. Ineffective coping and high stress levels in individuals with chronic illnesses can result in depression, which is the most common coping problem in patients with lupus [3].
Considerable emotional support may be required by the patient with lupus to cope with the chronic disease. More than 50% of all individuals with lupus experience emotional problems secondary to their illness [4]. Some individuals are overwhelmed with having a disease. They may find professional counseling to be an important means of managing their condition.
A method called cognitive mapping has been used to ascertain how women with lupus represent their illness [48]. In one study, 20 female patients with lupus were interviewed in a convenience sample and asked to generate major concepts for the question, "When you think of living with lupus, what words come to mind?" In addition, participants determined the positive and negative relationship among the identified words or phrases. The cognitive mapping procedure generated 355 concepts from 20 participants, with 192 unduplicated concepts. Pain was the most commonly identified concept reported by participants. The report concluded, "although diagnosed with the same illness, women presented with different mental representations of the illness" [48].
In another study, Baker and Wiginton surveyed 38 women to assess their perceptions and coping with lupus. They concluded that many women were relieved to have been diagnosed with lupus, as they finally had a label for their symptoms. Study participants also desired "current and accurate information about lupus" [44].
Social support can have a positive impact on individuals diagnosed with lupus. Stewart defines social support as "interactions with family members, friends, peers, and health professionals that communicate information, esteem, practical aid, or emotional help" [49]. Stewart found that social support may enhance coping and that these interactions helped to moderate the impact of stressors and promote health [49]. Social support can be gained from various sources, including a spouse or partner, other family members, friends, co-workers, neighbors, volunteers, church members, community members, online or in-person self-help mutual aid groups, or healthcare professionals [49].
Seeking and gaining social support can be difficult when one is experiencing a chronic illness such as lupus because tremendous energy is necessary to maintain social networks [45]. Lupus symptoms, as well as treatment side effects, can present a challenge for individuals in maintenance of their pre-illness social relationships and activities. Furthermore, to gain necessary support, individuals with lupus should understand and then communicate to others what they need to assist them in managing their disease.
Keller noted similar findings in her research on social support and psychological distress in women with lupus. She concluded that "younger women with lupus were more psychologically distressed than older women with lupus and that women with shorter duration since diagnosis were more distressed" [50]. Keller also found that the perception of having social support and being satisfied with the social support were more important than the number of social supports [50]. Thus, perception of and satisfaction with social support have been found to reduce psychological distress.
One important potential source of assistance can be support groups. It has been noted that "participating in a support group can provide emotional assistance, boost self-esteem and morale, and help to develop or improve coping skills" [5]. Successful support groups can assist patients to gain insights into how to live with their lupus [51]. Darner found that women with lupus who had been diagnosed for longer periods of time had a healthier psychosocial adjustment [52]. Therefore, those newly diagnosed with lupus may require more support and interventions to aid in psychosocial adjustment. Findings indicate that "support groups, self-help groups, and peer counseling…may facilitate the individual's achievement of a positive adjustment to the newly diagnosed illness" [52]. Self-help groups offer patient education on lupus disease management, and it is recommended that those newly diagnosed with lupus receive support via peer groups. Darner concludes that "involvement in self-help/support groups by the majority of subjects was thought to have influenced positively the psychological and social adjustment of the SLE women" [52].
Support groups provide an avenue for the exchange of feelings and ideas regarding lupus. Phillips, founder of the Center for Coping, stated "self-help or support groups can be incredibly helpful and are some of the best sources of support for people with lupus" [4]. Support groups also restore a sense of autonomy and self-reliance, resulting in a reduction in dependency for the group participants [53]. These groups can provide ideas on how to effectively cope with serious illness and manage problems associated with the condition. Lupus support groups can help members "realize they have the inner strength to cope with existential dilemmas of life as well as the comfort of knowing there are others like themselves" [51]. Gartner states that "in the case of most chronic illnesses, the issue is care not cure, and the mutual-support group can play a powerful role in helping individuals cope with their illness" [53].
Online social support groups may be an important resource for patients with lupus, especially those who live in rural areas or are unable to leave their homes. Patients may be directed to one of many support groups available online, including LupusConnect (https://www.lupus.org/resources/lupusconnect) or MyLupusTeam (https://mylupusteam.com).
Studies indicate that learning about one's disease process can aid individuals. In addition, it can increase the likelihood of participation in one's care and improve disease outcome [5]. One important voluntary organization that is dedicated to providing such services is the Lupus Foundation of America (LFA). The LFA's mission is to "improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. [The LFA is] focused on achieving the following disease-specific outcomes: reduce time to diagnosis; ensure people with lupus have an arsenal of safe and effective treatments; and expand direct services and increase access to treatment and care" [55]. The LFA has created the World Lupus Federation, which has more than 200 groups, with the goal of bringing greater attention to end lupus. The LFA provides education services, referrals, health fairs, newsletters, publications, and seminars, and works toward funding research, accelerating delivery and improving cost of medication, and spreading awareness. Support is provided to patients with lupus and their families and friends through the LFA organization [5]. The foundation's website is https://www.lupus.org. To increase national recognition for lupus, May has been designated as Lupus Awareness Month.
The Lupus Research Alliance is the "world's largest nongovernment funder of lupus research. The organization aims to transform treatment while advancing toward a cure by funding the most innovative lupus research, fostering diverse scientific talent, stimulating collaborations and driving discovery toward better diagnostics, improved treatments, and ultimately a cure for lupus" [56]. The Lupus Research Alliance provides information, research and clinical trials information, and community outreach for those affected by lupus. Information may be accessed at https://www.lupusresearch.org [56].
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health, is a leader and coordinator of biomedical research regarding lupus [5]. NIAMS produces free lupus information that may be accessed online at https://www.niams.nih.gov/health-topics/lupus.
Patient A is a woman, 20 years of age, living in a small, rural town. In October, she suddenly begins experiencing fatigue, anxiety, and heart palpitations. She has recently given birth to her second child, a daughter. She contacts her physician, who believes the symptoms are related to the stress of having given birth in addition to caring for her toddler son. The physician recommends that Patient A rest and obtain some help caring for her two small children.
Patient A's symptoms worsen and then gradually resolve. Her family encourages her to take her physician's advice and try to reduce the stress in her life. Approximately two years after the initial symptoms, Patient A begins experiencing abdominal pain. Her rural family physician refers her to an internist in a large metropolitan city 50 miles from her home. The internist examines her and preliminarily determines that due to the patient's age and symptoms, her gallbladder is most likely causing the abdominal pain. The internist prescribes a low-fat diet and advises Patient A to adopt healthy lifestyle practices, including increased physical activity.
Five years after the symptoms initially began, Patient A becomes pregnant with her third child. During the sixth month of her pregnancy, the patient begins to experience problems. She has premature contractions, increased fatigue, headaches, and swelling in her legs. Her physician prescribes bed rest due to overexertion. During the last three months of pregnancy, Patient A remains on bed rest and the pregnancy is monitored with bi-weekly visits and ultrasounds. Her family plays a central role in helping her with housekeeping and childcare for her two children. However, she is forced to take a leave of absence from her job due to the premature labor. She delivers a healthy baby girl in September.
Shortly after the birth of her third child, Patient A begins experiencing new and puzzling symptoms. Her ankles and knees begin to swell, and the edema is noted bilaterally. She also starts to complain of joint pain in her ankles, knees, elbows, wrists, and fingers. Patient A has difficulty climbing a flight of steps or dancing. Rest and over-the-counter pain medication relieve her symptoms, but it is difficult for her to find time for much rest due to the responsibilities of caring for a family and working full-time. Her family is very concerned about her health and wonders why the physician is not able to find a cause for her problems.
The winter brings a new intolerance to low temperatures. While Patient A has never liked cold weather, suddenly she is having a problem with her hands and feet becoming painful and discolored when she is exposed to cold. Her extremities become painful, stiff, and altered in color when exposed to cold temperatures. Patient A finally returns to her rural family physician in March. He is perplexed; he is not sure what is causing the young woman's problems. The physician decides to send Patient A to see a rheumatologist in the same metropolitan area as the internist.
The rheumatologist examines the patient and runs several blood tests. Patient A's ANA test is positive at 1:640. Her anti-dsDNA, anti-Sm tests are negative (normal: negative test with no LE cells noted). The rheumatoid factor is negative, and her sedimentation rate is 62 mm/hour (normal: up to 20 mm/hour for women).
The rheumatologist tells Patient A that he cannot be sure of her condition, but that he is considering the possibility that it could be lupus. He emphatically tells her, however, that it is not a positive diagnosis, and he certainly does not want to label her with such a devastating disease unless he is certain. He prescribes an anti-inflammatory medication, naproxen, and tells her to return home and rest. Patient A is frustrated—no one has been able to find an answer to why she feels so sick. She tries to talk to her family and friends, but they do not seem to understand what she is going through. Even the physicians do not seem to hear what she is telling them.
While medication reduces the pain and swelling in her joints, Patient A continues to experience fatigue, abdominal pain, and intolerance to cold weather. She is frustrated and feels as if no one is listening to her complaints. Her spouse, family, and friends do not understand why she feels so bad when she looks as if there is nothing really wrong with her. To Patient A, it seems as if she will never feel healthy again.
In the summer of the following year, Patient A experiences a strange red, raised rash with itching after having been out in the sun. She has always enjoyed the outdoors, and while she has been sunburned in the past, she has never had a rash. In addition, she begins to develop small, raised sores on her legs and arms. The joint pain, swelling, and fatigue continue.
Convinced that there must be something wrong with her, Patient A begins researching information on rheumatologic conditions. Based on her symptoms and the lab test results performed in the past, she begins to suspect that she has lupus. She begins to inquire around the town in which she lives to determine if anyone knows of a good rheumatologist that they like and trust. She finally locates a rheumatologist and makes an appointment as soon as possible.
At the first visit to the new rheumatologist's office, the physician elicits the patient's long medical history and description of her numerous symptoms. He examines her and obtains lab work, including a CBC, ANA, anti-dsDNA antibody test, and complement series, as well as a skin biopsy of the lesions on her legs. The skin biopsy results indicate small vessel vasculitis. The following lab results are recorded:
ANA: 1:640 (normal: No ANA detected in a titer with a dilution 1:32)
Anti-dsDNA antibody test: Elevated (normal: low or none)
Complement assay: Decreased C3 level at 43 mg/dL (normal: 55–120 mg/dL) and decreased C4 level at 14 mg/dL (normal: 20–50 mg/dL)
Red blood cell count: 3.8 million/mm3 (normal: 4.2–5.4 million/mm3 for women)
Hemoglobin: 10.5 g/dL (normal: 12–16 g/dL for women)
Hematocrit: 35% (normal: 37% to 47% for women)
White blood cell count: 6,000/mm3 (normal: 5,000–10,000/mm3 for women)
Platelets: 138,000/mm3 (normal: 150,000–400,000/mm3)
After completing all of the tests, the rheumatologist sits with the patient and her spouse and tells them that he is certain that she has systemic lupus erythematosus. She meets the entry criterion of an ANA titer ≥1:80 of the EULAR/ACR criteria for classification and has the following additive criteria: butterfly rash/facial erythema (acute cutaneous lupus, 6 points), nonerosive arthritis (joint involvement, 6 points), hematologic or blood disorder (autoimmune hemolytic anemia, 4 points), immunologic disorder (abnormal anti-dsDNA antibody test, 6 points), for a total of 22 points. Patient A meets classification criteria with the entry criterion of ANA titer being met, at least one of the clinical domains being met, and a score of at least 10 points [28].
The physician describes the disease in great detail to Patient A and her husband and answers all of their questions. The physician believes that the patient has had lupus for more than seven years, beginning with her initial symptoms. He initiates hydroxychloroquine for long-term disease control and prescribes a course of oral prednisone to control the current inflammatory manifestations. The prednisone dose will be tapered according to clinical response. Given the possibility of persistent or recurrent systemic activity, the physician evaluates the need for steroid-sparing immunosuppressive therapy, such as azathioprine or mycophenolate mofetil. Kidney involvement and immune-mediated cytopenias are assessed before finalizing the regimen. The physician reassures Patient A as she leaves his office that he will be available for her and will help her manage the disease.
As Patient A leaves the rheumatologist's office, her feelings are mixed. She is thankful to finally know she is not crazy and to have a diagnosis. She is also angry and bitter that it took seven years and four physicians to finally find a cause for her symptoms. She is relieved that she can finally tell her family and friends why she has felt so sick. She is also very afraid because she is not certain what her future will hold now that she has been diagnosed with the chronic disease lupus.
This case study provides one example of the physical and psychological experiences associated with lupus. The struggles Patient A experiences in an attempt to diagnose her chronic illness are documented, as well as the vagueness of her symptoms. This woman's experience provides a brief glimpse into the challenges of obtaining a diagnosis and of living with lupus.
Lupus is a chronic disease that primarily impacts women in their childbearing years. While the exact cause of lupus is unknown, possible causes include genetic or hereditary factors, immunologic dysfunction, and environmental factors. Lupus can impact any system of the body with mild to life-threatening symptoms. The diagnosis of lupus can present a challenge to healthcare providers, as symptoms are often vague. Diagnosis is based on clinical judgment, supported by laboratory findings; the EULAR/ACR classification criteria can help guide the evaluation. There is no cure for lupus, but various interventions, including medications, can be utilized to prevent, treat, and slow disease progression. Due to the chronic nature of lupus, patients can expect to face many years of dealing with a disease that impacts multiple facets of their life. Effective coping strategies are essential in the management of any chronic illness, including lupus.

1. 1. Falvo DR.Medical and Psychosocial Aspects of Chronic Illness and Disability. 6th ed. Sudbury, MA: Jones and Bartlett Publishers; 2017.
2. National Institute of Allergy and Infectious Diseases.Lupus: A Patient Care Guide for Nurses and Other Health Professionals. 3rd ed. NIH Publication No. 06-4262. Bethesda, MD: U.S. Department of Health and Human Services; 2006.
3. Wallace DJ.The Lupus Book: A Guide for Patients and Their Families. 6th ed. New York, NY: Oxford University Press; 2012.
4. Phillips RH.Coping with Lupus: A Practical Guide to Alleviating the Challenges of Systemic Lupus Erythematosus. 4th ed. New York, NY: Penguin Putnam; 2012.
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Health Topics: Systemic Lupus Erythematosus. Available at https://www.niams.nih.gov/health-topics/lupus. Last accessed October 27, 2026.
6. Centers for Disease Control and Prevention. Systemic Lupus Erythematosus. Available at https://www.cdc.gov/lupus/signs-symptoms. Last accessed October 27, 2026.
7. Carter EE, Barr SJ, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact.Nat Rev Rheum. 2016;12(10):605-620.
8. Lupus Foundation of America. Lupus Facts and Statistics. Available at https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed October 27, 2026.
9. Daly R, Al Sawah S, Foster S, et al. FRI0420 Health related quality of life in lupus differs by how patients perceive their health and how often they experience flares: findings from a cross-sectional online survey in the United States.Ann Rheum Dis. 2015;74:578-579.
10. Lupus Foundation of America. Lupus and Skin Rashes. Available at https://www.lupus.org/resources/lupus-and-skin-rashes. Last accessed October 27, 2026.
11. U.S. Department of Health and Human Services, Office on Women's Health. Lupus. Available at https://womenshealth.gov/lupus. Last accessed October 27, 2026.
12. Company-Quiroga J, Alique-García S, Romero-Maté A. Current insights into the management of discoid lupus erythematosus.Clin Cosmet Investig Dermatol. 2019;12:721-732.
13. LexiDrug. Available at https://online.lexi.com. Last accessed October 27, 2026.
14. Lupus Foundation of America. Different Types of Lupus. Available at https://www.lupus.org/resources/what-is-lupus. Last accessed October 27, 2026.
15. Kauffman CL. Drug-Induced Lupus Erythematosus. Available at https://emedicine.medscape.com/article/1065086-overview. Last accessed October 27, 2026.
16. Mayo Clinic. Lupus: Symptoms and Causes. Available at https://www.mayoclinic.org/diseases-conditions/lupus/symptoms-causes/syc-20365789. Last accessed October 27, 2026.
17. Lupus Foundation of America. Understanding Your Risk for Lupus. Available at https://www.lupus.org/resources/risk-factors-for-developing-lupus. Last accessed October 27, 2026.
18. Remmers E, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.N Engl J Med. 2007;357(10):977-986.
19. Alexander LL, LaRosa JH, Bader H, Garfield S.New Dimensions in Women's Health. 8th ed. Sudbury, MA: Jones and Bartlett Publishers; 2020.
20. Lupus Foundation of America. How Lupus Affects the Bones. Available at https://www.lupus.org/resources/how-lupus-affects-the-bones. Last accessed October 27, 2026.
21. Lupus Foundation of America. What You Need to Know About Anemia. Available at https://www.lupus.org/resources/what-you-need-to-know-about-anemia. Last accessed October 27, 2026.
22. Testing.com. Complement. Available at https://www.testing.com/tests/complement/. Last accessed October 27, 2026.
23. Lupus Foundation of America. Common Diseases that Overlap with Lupus. Available at https://www.lupus.org/resources/common-diseases-that-overlap-with-lupus. Last accessed October 27, 2026.
24. Lupus Foundation of America. Lab Tests for Lupus. Available at https://www.lupus.org/resources/lab-tests-for-lupus. Last accessed October 27, 2026.
25. Pagana KD, Pagana TJ, Pagana TN.Mosby's Diagnostic and Laboratory Test Reference. 15th ed. St. Louis, MO: Mosby; 2021.
26. Booth S, Price E, Walker E. Fluctuation, invisibility, fatigue—the barriers to maintaining employment with systemic lupus erythematosus: results of an online survey.Lupus. 2018;27(14):2284-2291.
27. Lupus Foundation of America. Cognitive Dysfunction in Lupus is Prevalent and Not Associated with Disease Activity. Available at https://www.lupus.org/news/cognitive-dysfunction-in-lupus-is-prevalent-and-not-associated-with-disease-activity. Last accessed October 27, 2026.
28. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.Arthritis Rheumatol. 2019;71(9):1400-1412.
29. Janardana R, Haridas V, Priya V, et al. Maternal and fetal outcomes of lupus pregnancies: a collective effort by Karnataka Rheumatologists.Lupus. 2020;29(11):1397-1403.
30. Lupus Foundation of America. Medications Used to Treat Lupus. Available at https://www.lupus.org/resources/medications-used-to-treat-lupus. Last accessed October 27, 2026.
31. U.S. Food and Drug Administration. FDA News Release: FDA Approves Benlysta to Treat Lupus. Available at https://wayback.archive-it.org/7993/20170112024037/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm. Last accessed October 27, 2026.
32. Collins CE, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.Lupus Sci Med. 2016;3(1):e000118.
33. Touma Z, Sayani A, Pineau CA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.Rheumatol Int. 2017;37(6):865-873.
34. Serra SS, Pedrosa T, Falcão S, Branco JC. Severe interstitial lung disease and manic symptoms secondary to corticosteroids in a patient with systemic lupus erythematosus and secondary Sjögren's syndrome.Acta Med Port. 2017;30(3):246-250.
35. Dai X, Ding H, Mao D, Huang J. Prevalence of female sexual dysfunction among women with systemic lupus erythematosus: a systematic review and meta-analysis.Front Immunol. 2026;17:1673871.
36. American College of Rheumatology. Lupus. Available at https://rheumatology.org/patients/lupus. Last accessed October 27, 2026.
37. Bermas BL, Smith NA. Pregnancy in Women with Systemic Lupus Erythematosus. Available at http://www.uptodate.com/contents/pregnancy-in-women-with-systemic-lupus-erythematosus. Last accessed October 27, 2026.
38. Medline Plus. Miscarriage. Available at https://medlineplus.gov/ency/article/001488.htm. Last accessed October 27, 2026.
39. Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study.Ann Intern Med. 2015;163(3):153-163.
40. Clowse MEB, Oates J, Barnado A, et al. Implications of the accuracy of diagnostic algorithms for systemic lupus on our understanding of racial disparities in pregnancy outcomes.Rheumatology (Oxford). 2024;63(1):119-126.
41. Guettrot-Imbert G, Morel N, Le Guern V, et al. Pregnancy and contraception in systemic and cutaneous lupus erythematosus.Ann Dermatol Venereol. 2016;143(10):590-600.
42. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus.N Engl J Med. 2005;353(24):2550-2558.
43. Bernier M, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus.Arthritis Rheum. 2009;61(4):476-481.
44. Baker JA, Wiginton K. Perceptions and coping among women living with lupus.Am J Health Behav. 1997;21:129-136.
45. Albrecht K, Troll W, Callhoff J, Strangfeld A, Ohrndorf S, Mucke J. Sex- and gender-related differences in systemic lupus erythematosus: a scoping review.Rheumatol Int. 2025;45(7):160.
46. Lorig K. Self-management in chronic illness. In: Funk SG, Tornquist EM, Leeman J, Miles MS, Harrel JS (eds).Key Aspects of Preventing and Managing Chronic Illness. New York, NY: Springer Publishing; 2001: 35-41.
47. Dennis JM.Coping, Psychosocial Adjustment, and Health Status in Women with Systemic Lupus Erythematosus [dissertation]. Lawrence, KS: University of Kansas; 1998.
48. Wiginton KL. Illness representations: mapping the experience of lupus.Health Educ Behav. 1999;26:443-453.
49. Stewart MJ, Langille L. A framework for social support assessment and intervention in the context of chronic conditions and caregiving. In: Stewart MJ (ed).Chronic Conditions and Caregiving in Canada. Toronto: University of Toronto Press; 2000.
50. Keller SM. Social Support and Psychological Distress in Women with Systemic Lupus Erythematosus [dissertation]. Cleveland, OH: Case Western Reserve University; 1999.
52. Darner GF. Self-Concept and Psychosocial Adjustment in Women with Systemic Lupus Erythematosus [dissertation]. Long Island, NY: Adelphi University; 1991.
54. U.S. Food and Drug Administration. FDA Approves First Treatment for Pediatric Patients with Lupus. Available at https://www.fda.gov/media/140599/download. Last accessed October 27, 2026.
55. Lupus Foundation of America. Our Mission. Available at https://www.lupus.org/about-us. Last accessed October 27, 2026.
56. Lupus Research Alliance. Learn from Lupus. Available at https://www.lupusresearch.org. Last accessed October 27, 2026.
57. American College of Rheumatology. A New Era for the Treatment of Lupus. Available at https://rheumatology.org/patient-blog/a-new-era-for-the-treatment-of-lupus. Last accessed October 27, 2026.
58. Lupus Foundation of America. Lupus Foundation of America celebrates FDA approval of Saphnelo (anifrolumab-fnia) as a new treatment for lupus. Available at https://www.lupus.org/news/fda-approval-of-saphnelo-anifrolumabfnia-new-treatment-lupus. Last accessed October 27, 2026.
59. Chaichian Y, Utset TO. Targeted therapies in systemic lupus erythematosus: a state-of-the-art review.J Clin Cell Immunol. 2013;06:009.
60. Rodriguez-Garcia V, Dias SS, Isenberg D. Recent advances in the treatment of systemic lupus erythematosus.Int J Clin Rheumtol. 2014;9(1):89-100.
61. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.Ann Rheum Dis. 2024;83(1):15-29.
62. Brown GJ, Cañete PF, Wang H, et al. TLR7gain-of-function genetic variation causes human lupus.Nature. 2022;605:349-356.
63. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries.Arthritis Rheumatol. 2021;73(6):991-996.
64. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases.Arthritis Rheumatol. 2020;72(4):529-556.
65. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).Ophthalmology. 2016;123(6):1386-1394.
66. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis.Kidney Int. 2024;105(1S):S1-S69.
67. Satoh M, Chan EKL, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States.Arthritis Rheum. 2012;64(7):2319-2327.
68. Genentech. Gazyva (obinutuzumab) prescribing information. South San Francisco, CA: Genentech, Inc.; 2025.
69. Dawson D, Greenlund KJ, Barbour KE. Systemic lupus erythematosus mortality among decedents aged ≥15 years—United States, 2018–2023.Arthritis Care Res (Hoboken). 2026;78(9):1188-1194.
70. Lin DH, Murimi-Worstell IB, Kan H, et al. Health care utilization and costs of systemic lupus erythematosus in the United States: a systematic review.Lupus. 2022;31(7):773-807.
71. Kirakossian D, Ghosh P. Drug-induced lupus, a one-time hit or a harbinger of future autoimmunity: a case report.Perm J. 2020;24.
1. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2025.Br J Dermatol. 2026;194(2):e56-e73. Available at https://doi.org/10.1093/bjd/ljaf452. Last accessed October 30, 2026.
2. Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus.Arthritis Care Res (Hoboken). 2026;78(7):815-839. Available at https://doi.org/10.1002/acr.25690. Last accessed October 30, 2026.
3. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.Ann Rheum Dis. 2024;83(1):15-29. Available at https://doi.org/10.1136/ard-2023-224762. Last accessed October 30, 2026.
Mention of commercial products does not indicate endorsement.